Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looks like Ehrlich's descent into oblivion has deprived you of getting more shares of this gem.
It was 100% correct when it was written. This message, which appears in the IPIX trading session now when a buy order is attempted, did NOT appear when I said they would take your order:
Sounds like you've been saved from even more stupendously stupid "investing" decisions.
It seems your patron saint, St. Joseph of Cupertino, has been looking out for you.
Just be grateful.
That's the first reasonable forward path I have heard for Bri in quite some time. Thanks for mentioning it.
Your information about Schwab is not correct.
“Your last appearance had you asking…”
What a yenta. Sheesh!
Understandable why you would have the blahs if you are invested in this mess. At least you recognize your bad choice.
Bril+Caspofungin to form a super antifungal under a brand new patent.
Actually, Merck's patent expired in 2017, and there are 3 generics.
Caspofungin (brand name Cancidas) is a lipopeptide antifungal drug from Merck & Co., Inc."
Remdesivir is owned by Gilead .
Both drugs work great with Brilacidin.
Hoping that Leo is forming a biding war between the 2 Big pharma companies.
Hey! Long time no see. Your last appearance had you asking "Is trading halted?" on a day that 125million shares were traded. People with IPIX shares at the close of trading that day held them at $.0892, about 42 times what they go for today.
Don't be such a stranger!
Blah Blah Blah Blah…
What happened to your Feb 6th proclamation...
of "a significant positive press release in 6-8 weeks that will move the share price big-time whereby investors on the sideline would be scrambling to buy IPIX"?
Or was this just another fail in a long list of failed prognostications? As many times as you've faceplanted you must look like a pug.
Questions that are never answered. He/she sounds a lot like early years Leo before he vanished...big on hype/hope with little to no delivery.
Why don't you tell us what is positive about a .000 to .00 stock? This mess has been completely decimated and what is left is a one-person company, with only one board member who is also the only person in the company, where the shares cannot even be traded on the lowly pink sheets but are on some "expert" wasteland, where, consequently, there is little no volume and where most accounts will not allow you to buy the shares, where the "company" was hit with a major judgement that put it in the red and which came about because the CEO was asleep-at-the-wheel, where there is no longer any communication from the CEO to shareholders or any avenue for communication, where the one-man company maintains a website filled with stale information that has become misinformation, where there are no longer any filings and no transparency, where efforts to license or sell or achieve any degree of profitability from its one remaining drug have all failed (Locust Walk, Alfasigma, etc.), and where the CEO spent $4 million from his cash strapped mess to buy into some laser company where transparency is lacking and there is virtually no information about the financial status of that company (costs v anticipated sales, anticipated income, profitability projections, etc.). A dirty shell is all that is left.
Anything positive about IPIX is a figment of your imagination.
Anything positive about IPIX must be killed. Remember, the company is "dead."
Interesting when Frenchy posts, there is a direct attack on him all the time.....why is that????
"Thank you for this Schwab information. If it is true and I can buy I will make a new account."
Did you find it to be true? (I don't care if you made a new account.)
And what happened to this?
Have you managed to scoop up those 3 million shares yet?
And where are those promising press releases you were boasting about in June of last year? You can't even find the vanished CEO let alone any positive press releases. Doesn't look like there is much of anything left now.
If it so promising, why has no interest materialized? Do you really think an idiot like Erhlich can get anything promising accomplished? Look at the mess he has left this company in.
News flash - there’s no market for IPIX or B. Dead.
I'm guess I'm not so concerned with IPIX license agreement with having William Degrado still on board. I figure if UP wanted B back they could have rescued it out of Polymedix bankruptcy. It was good to see the latest peer review stating William DeGrado's contributions to B's anti-fungal studies. We have anti-fungal testing here and in Brazil. Hopefully something positive comes out of this for those holding shares.
I agree that there's a lot of interest in anti-fungal drugs particularly if continued climate change will increase and possibly compound the issue.
While I believe that B showing promise is the legitimate driver I'm wondering if applying for a patent is regarded simply as a way of placing a marker on what could be a promising drug. Also, there has to be an awareness of B nearing the end of license and does that have anything to do with the surge in patents?
I would hate for B to be swooped up by someone after IPIX investors have spent so much time and money pushing it to the 49 yard line. It would suck to have to watch some pharma with money, resources, and FDA influence spike 'our' B in the end zone.
Leo did not demonstrate well in his management of the office lease. Over the past few years I do not feel Leo has been putting forth the effort to advance B as his compensation should warrant. I guess we wait and see if Leo has the capability and the motivation to pursue bringing B to some degree of fruition.
I would think an effective new anti-fungal combination of Bril + Caspofungin would be of great interest to BP
Come on Leo, sell it all for .50!
Looks to be a new patent app combining/using Bril + Caspofungin?
Does anyone know what the fee is for filing a patent application such as the one PJ007 posted? A cursory look indicated that a "non-electronic" application is $200-$400 and getting a patent approved spins up numbers between $8 - $15k all the way to pharmaceutical patents costing over $2M.
What I'm trying to determine is a degree of seriousness behind these patent applications. If it's just a few dollars for an online application it could be somewhat frivolous, a low budget attempt to cover all bases, or a desire to muddy the waters. If it's the University of Sao Paulo I imagine there would be some justification required before spending even a few hundred dollars. Universities tend to be frugal with research expenditures.
I understand that there are obstacles beyond the patent office and would appreciate if responses centered on what the application stage costs.
I don't know but I sure would love to know.....
Good catch, why do you think another patent has been secured? Preparing for a sale?
Well I want to know where the frick Leo is? Pathetic he has just disappeared
wow, another patent published today on Brilacidin
https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/20240139188
What is going on ???
I tried to call BM via what’s app and could not get through..
He has been mostly missing from access to stock holders for quite a while. But the real disgrace, imo. is not that, it is the million plus he and a friend have been extracting annually, these last few years. Lots of money for a company with no office, no lab, no post docs, no news letter, etc. He has tried to enhance value a few times, and that is to his credit; but the fact that we here have subsidized his stock play with nothing to show for it but losses, is the problem, not denying his general absence remains a disgrace, to use your words.
Waldo Ehrlich has completely vanished. What a disgrace.
I don't have either notation but they look like footnotes. Are 3 and 4 described further down the page?
That does make sense… but why 3 and 4
Interesting, phone has a 3 and PC has a 4 that’s the only position in all my investments that has those numbers
What page are you looking at? My Schwab account doesn't have that notation on the Position page....phone or computer.
Perhaps it’s referring to decimal position?
Might mean 4 days left until a total loss. See if the number changes to (3) tomorrow and report back.
Question: what does the little 4 mean on my Charles Schwab $0.0015(4)
ABSSSI - In February 2016, the Company submitted a Special Protocol Assessment (SPA) request, along with a final protocol, to the FDA, for a Phase 3 clinical trial of Brilacidin for the treatment of Acute Bacterial Skin and Skin Structure Infection (ABSSSI) caused by gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). We received from the FDA comments and considerations for incorporation into our study design. Management decided to delay its response to the FDA due to the low price per share of our common stock and the many multiple million dollar costs associated with a Phase 3 program. Our strategy, for now, is to achieve success with other trials and attract partnering opportunities that may provide significant upfront payments and milestone payments, which can then be used to fund the ABSSSI program. We see ABSSSI as the appropriate gateway indication in infectious diseases, enabling potential further studies of Brilacidin’s use for implant coating and biofilm infections.
https://www.sec.gov/ix?doc=/Archives/edgar/data/1355250/000147793223007158/ipix_10k.htm (2023 10-K)
Warning! This security is traded on the Expert Market
The Expert Market® serves broker-dealer pricing and investor best execution needs. Quotations in Expert Market securities are restricted from public viewing. OTC Markets Group may designate securities for quoting on the Expert Market when it is not able to confirm that the company is making current information publicly available under SEC Rule 15c2-11, or when the security is otherwise restricted from public quoting.
https://www.otcmarkets.com/stock/IPIX/overview (today)
Followers
|
979
|
Posters
|
|
Posts (Today)
|
2
|
Posts (Total)
|
402726
|
Created
|
05/10/08
|
Type
|
Free
|
Moderators zandant Minnesinger sunspotter snayeman loanranger frenchbroad |
Innovation Pharmaceuticals Inc. (IPIX)
$IPIX NEWS - http://ipharminc.com/press-release
SEC Filings https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany
From the most recent 10-K:
There are doubts about our ability to continue as a going concern.
We have generated revenue of $0 and $18,000 for the fiscal years ended June 30, 2023 and 2022, respectively and have an accumulated deficit of $125.3 million through June 30, 2023. These factors raise substantial doubt about our ability to continue as a going concern.
We need to raise substantial additional capital in the future to fund our operations and we may be unable to raise such funds when needed and on acceptable terms, which could prevent us from fully implementing our business, operating and development plans.
We currently have an approximate $1.0 million cash balance as of the date of this filing, but that is insufficient to complete the development and commercialization of any of our proposed products. We expect to incur costs of approximately $1.8 million in the upcoming fiscal year ending June 30, 2024 to operate our business in accordance with our business plans and budgets.
We have limited experience in drug and formulation development, the conduct of clinical trials, and may not be able to successfully develop any drugs.
Development of pharmaceutical products is a risky and time-consuming process subject to a number of factors, many of which are outside of our control. We are subject to regulatory authority permissions and approvals, most importantly the FDA. Our drug candidate(s)/indications are at early and mid-stages of development. Consequently, we can provide no assurance of the successful and timely development of new drugs, and the failure to do so could cause us to cease operations.
We may elect to deregister our common stock under the Exchange Act and suspend our reporting obligations. Such deregistration and suspension would result in less disclosure about us and may negatively affect the liquidity and trading prices of our common stock.
http://www.ipharminc.com/
About Innovation Pharmaceuticals Inc.:
Established in 2007, and headquartered in Wakefield, Massachusetts, Innovation Pharmaceuticals Inc. (formerly Cellceutix Corporation) is a publicly traded biopharmaceutical company dedicated to discovering and advancing innovative medical therapies with dermatology, oncology, anti-inflammatory and antibiotic applications.
Through ongoing research and drug development efforts, Innovation is focused on improving the clinical care of patients, as well as growing shareholder value. Our team consists of a diverse and accomplished group of professionals working together toward achieving this common goal.
IPIX CEO - "The Company historically devoted most of its efforts and resources on business development, regulatory matters, and clinical trials. Presently, the Company does not have sufficient financial resources to advance our drug candidates meaningfully." "In general, we expect to concentrate on product development and engage in a limited way in product discovery, avoiding the significant investment of time and financial resources that is generally required for a promising compound to be identified and brought into clinical trials." Source - https://www.sec.gov/ix?doc=/Archives/edgar/data/1355250/000147793223003414/ipix_10q.htm
More information is available at http://www.ipharminc.com.
Management: http://www.ipharminc.com/senior-management/
Scientific Advisors: http://www.ipharminc.com/scientific-advisors/
Clinical Trials: https://clinicaltrials.gov/ct2/results?cond=&term=%22Innovation+Pharmaceuticals%2C+Inc.%22++&cntry=&state=&city=&dist=&Search=Search&flds=abcefgps
Trials under previous name: https://clinicaltrials.gov/ct2/results?cond=&term=cellceutix&cntry=&state=&city=&dist=&Search=Search&flds=abcefgps
Product Pipeline: http://www.ipharminc.com/therapeutic-areas/
Recent News and Press Releases:
https://finance.yahoo.com/quote/IPIX?p=IPIX
http://www.ipharminc.com/press-release/
SEC Filings (CIK:0001355250): https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany
Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com
Share Structure: See SEC filing link above for current share structure
Investor Relations:
http://www.ipharminc.com/new-faq/
http://www.ipharminc.com/contact-us-1
Chart: https://stockcharts.com/h-sc/ui?s=IPIX
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock. Being a moderator isn’t a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |